Navigation Links
Covance Reports Full-Year 2007 Revenue Growth Of 15.4% and Seventh Consecutive Year of EPS Growth in Excess of 20%
Date:1/30/2008

ar to $207.9 million, compared to $167.2 million in the fourth quarter of 2006, representing exceptionally strong performances across the segment's service offerings. For the full year 2007, net revenues increased 22.9% to $777.7 million compared to $632.8 million in 2006.

Operating income for the fourth quarter of 2007 increased 33.3% to $51.5 million compared to $38.6 million for the fourth quarter of last year. Operating margins for the fourth quarter of 2007 grew 170 basis points to 24.8% versus 23.1% in the fourth quarter of the prior year on the strong performances across the segment. Full year operating margins grew 90 basis points to 25.2% compared to 24.3% in the prior year. We expect continued expansion in Early Development operating margin in 2008 on a full-year basis.

Late-Stage Development

($ in millions) 4Q07 4Q06 Change FY 2007 FY 2006 Change

Net Revenues $203.1 $175.8 15.6% $768.8 $707.4 8.7%

Operating

Income $32.6 $32.7 -0.4% $128.1 $123.6 3.6%

Margin % 16.0% 18.6% 16.7% 17.5%

The Late-Stage Development segment includes central laboratory, Phase II- III clinical development, and commercialization services (periapproval services and market access services). Late-Stage Development net revenues for the fourth quarter of 2007 grew 15.6% to $203.1 million compared to $175.8 million in the fourth quarter of 2006. Central laboratory and clinical development services each delivered revenue growth in excess of 20% in the quarter. Full year Late-Stage Development net revenues grew 8.7% to $768.8 million compared to $707.4 million in 2006. The sale of the centralized ECG business, which will remain in the base of the comparison year, will impact revenue growth in 2008 by approximately 350 basis points.

Operating income for the fourth quarter of 2007 was $32.6 million compared to $32.7 million in the fourt
'/>"/>

SOURCE Covance Inc.
Copyright©2008 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11

Related biology technology :

1. Covance Inc. Invites You to Join the Webcast of Its Third Quarter 2007 Financial Results Conference Call
2. EpiCept Reports Expansion of Clinical Development For Licensed Cancer Compound
3. QMed, Inc. Reports July Medicare SNP Enrollments
4. Phlo Affiliate Reports Expanded Coverage to Oregon Border
5. Healthcare Technologies Reports Loss for 2007 Second Quarter & Six Months Results
6. Dragon Pharmaceutical Reports Growth in Sales and Profits during Second Quarter of 2007
7. Carrington Reports Second Quarter 2007 Results
8. Avitar Reports Third Quarter Financial Results for Fiscal 2007
9. Response Genetics Reports Second Quarter 2007 Financial Results
10. Cadence Pharmaceuticals Reports Second Quarter 2007 Financial Results
11. Transgenomic, Inc. Reports Second Quarter 2007 Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:7/24/2014)... Keryx Biopharmaceuticals, Inc. (Nasdaq:KERX) (the "Company") announced the publication ... 3 study of Zerenex (ferric citrate), the Company,s investigational ... hyperphosphatemia in patients with end-stage renal disease (ESRD) on ... with FErric CiTrate in EsrD) was published online today ... Nephrology ( JASN ). , This ...
(Date:7/24/2014)... , July 24, 2014  Now available is a ... Rehealth Regenerative Therapies , located in ... physically active people a new health option: stem ... of age, countless patients suffer from joint and muscle ... as muscle tears, torn rotator cuff, tennis elbow, and ...
(Date:7/24/2014)... worldwide rely on sophisticated equipment, trained personnel, and ... areas against terrorist attacks. A revolutionary new electronic ... make their job much easier. , The groundbreaking ... Tel Aviv University ,s School of Chemistry and ... the Herzliya company Tracense, picks up the scent ...
(Date:7/24/2014)... Distinguished Professor of Engineering at the University of ... solve problems in energy engineering, environmental sustainability and ... zeolites, porous rock with a well-defined, crystalline structure. ... so precisely decided that zeolites can separate molecules ... an angstrom (one-tenth of a nanometer), making them ...
Breaking Biology Technology:Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 2Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 3Zerenex (ferric citrate) long-term Phase 3 study results published in JASN 4Stem Cells In Sports Injuries, Joints And Muscular Pain 2Stem Cells In Sports Injuries, Joints And Muscular Pain 3Nano-sized chip 'sniffs out' explosives far better than trained dogs 2University of Delaware researcher describes new approach for creating organic zeolites 2
... , , WATERTOWN, Mass., Sept. 10 ... breakthrough synthetic chemistry technology announced today that it will ... on the synthesis and antibacterial activity of analogs from ... at the 49th Interscience Conference on Antimicrobial Agents and ...
... STOCKHOLM, September 10 Pergamum AB has announced ... wound healing interests, and create a broad-based therapeutic ... The Pergamum product pipeline consists of five ... Indications covered within the,portfolio include improved wound healing ...
... , , , ... Inc. (PTC) today announced the initiation of a Phase 3 ... in patients with nonsense mutation cystic fibrosis (nmCF). Patients ... conductance regulator (CFTR) protein, a chloride channel necessary for normal ...
Cached Biology Technology:Tetraphase Presents Study Results for Novel Classes of Antibiotics from its Breakthrough Synthetic Chemistry Platform at ICAAC 2009 2Pergamum to Provide Effective Development of Innovative Dermatology and Wound Healing Companies 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 2PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 3PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 4PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 5PTC Therapeutics Initiates Registration-Directed Phase 3 Trial of Ataluren in Cystic Fibrosis 6
(Date:7/24/2014)... vision specialist at The University of Texas Health Science ... a grant to help Harris County residents whose vision ... , Even with corrective lenses, many people with low ... a variety of low vision devices, such as telescopes, ... loss. , Iyer is using the three-year, $164,645 SightFirst ...
(Date:7/24/2014)... The Atlantic Forest is a hotspot of biodiversity and ... (frogs, tree-frogs, and toads) in the world. However, current ... past few years has been an increase in the ... with the advance of molecular techniques and availability of ... extensive number of samples for molecular and morphological analysis, ...
(Date:7/24/2014)... N.J. A yearlong study funded by the New ... Edward J. Bloustein School of Planning and Public Policy ... in Sandy-affected towns are skeptical about the likelihood of ... survey respondents, 45 percent indicated they were "pessimistic" or ... by Superstorm Sandy would be rebuilt better than they ...
Breaking Biology News(10 mins):UTHealth Dr. Bhavani Iyer awarded low vision grant 2A tiny new species of frog from Brazil with a heroic name 2Rutgers study explores attitudes, preferences toward post-Sandy rebuilding 2
... China, September 12, 2013BGI Tech Solutions Co., LTD, ... largest genomics research organization, and South Texas Accelerated ... collaborating on the San Antonio 1000 Cancer Genome ... link genetic alterations that underlie different cancers to ...
... Society of America (ESA) is proud to announce ... Grants. These travel grants, which will help entomology ... in Austin this November are funded by ... Plant-Associated Insects and Nematodes. The grants were created ...
... A tiny number of Asian carp could establish a ... to new research from the University of Waterloo. , Published ... from Professor Kim Cuddington of the Faculty of Science at ... with the introduction of 20 fish into the Great Lakes, ...
Cached Biology News:BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project 2BGI and START initiate collaboration to advance unique San Antonio 1000 Cancer Genome Project 3Entomological Society of America names winners of 2013 student travel grants 2Entomological Society of America names winners of 2013 student travel grants 3Entomological Society of America names winners of 2013 student travel grants 4Entomological Society of America names winners of 2013 student travel grants 5Entomological Society of America names winners of 2013 student travel grants 6Entomological Society of America names winners of 2013 student travel grants 7Entomological Society of America names winners of 2013 student travel grants 8Tiny number of Asian carp could be big problem for the Great Lakes 2
... Adhesive seal tabs • Reusable, ... can be quickly assembled and disassembled for ... specimens of any thickness with up to ... three chambers per slide. Minimize specimen handling, ...
12 breakable polypropylene strips of 8 wells each held in a rigid frame. Ideal for antibody assays....
... for in vitro diagnostic assays, all EIA/RIA ... for uniform binding, high optical clarity and ... are part of the Certified Surface Chemistry ... be within QA release specifications. Linkage: This ...
... an aqueous solution that contains a purified ... in a saline solution, pH 6.5 ... methylisothiazolone and 0.02% bromonitrodioxane as a preservative. ... and stabilizer for biologically active components in ...
Biology Products: